Methods and compositions for treating hypoglycemic disorders
US-2019336584-A1 · Nov 7, 2019 · US
Methods and compositions for treating hypoglycemic disorders
US10987407B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10987407-B2 |
| Application number | US-201916258686-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 28, 2019 |
| Priority date | Jan 8, 2007 |
| Publication date | Apr 27, 2021 |
| Grant date | Apr 27, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism comprising administering to the subject an effective amount of a peptide comprising an amino acid sequence having at least 95% identity to SEQ ID NO:1. 2. The method of claim 1 , wherein the peptide is administered intravenously, parenterally, orally, intraperitoneally, subcutaneously, or by a combination thereof. 3. The method of claim 1 , wherein the peptide is administered subcutaneously. 4. The method of claim 1 , wherein the peptide is administered intravenously. 5. The method of claim 1 , wherein the peptide is administered by infusion. 6. The method of claim 1 , wherein the peptide is administered using a pump. 7. The method of claim 1 , wherein the congenital hyperinsulinism is associated with a genetic abnormality or mutation. 8. The method of claim 7 , wherein the genetic abnormality is associated with a mutation in a gene selected from the group consisting of a gene encoding a sulfonylurea receptor (SUR-1), a gene encoding glucokinase (GCK), a gene encoding glutamate dehydrogenase (GLUD-1), and a gene encoding mitochondrial enzyme short-chain 3-hydroxyacyl-CoA dehydrogenase (HADHSC). 9. The method of claim 1 , wherein the subject has congenital hyperinsulinism, and wherein the subject is over 10 years of age. 10. The method of claim 9 , wherein the subject is over 30 years of age. 11. The method of claim 1 , wherein the peptide is administered to a subject from 2 years to 10 years of age.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10987407B2 cover?
- This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analogue thereof.
- Who is the assignee on this patent?
- Univ Pennsylvania, Childrens Hospital Philadelphia, Childrens Hospital Of Philadelphia
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).